Led · Series A · Jun 2026

Tavo Biotherapeutics focuses on developing novel ophthalmology therapeutics aimed at preserving vision and improving outcomes for patients with glaucoma and retinal disease. Its lead program, TAV-001, is a potential disease-modifying topical therapy for glaucoma that employs a dual mode of action targeting the autonomic nervous system and is planned to enter a Phase 2 clinical trial in the second half of 2026. TAV-002 is a bispecific antibody that targets VEGF and an upstream signaling protein for serious retinal diseases, including wet and dry age-related macular degeneration and diabetes-related retinopathies. The company announced it raised $17 million in a Series A to advance these programs and expand research capabilities. In conjunction with the financing Tavo named Federico Grossi, M.D., Ph.D., as Chief Medical Officer and added Daniel Bradbury as Board Chairman. Board seats were also added for investor representatives from Pureos Bioventures and Polaris Partners.

Participated · Series A · Oct 2025

Adcytherix focuses on designing and developing highly selective antibody-drug conjugates that incorporate proprietary payloads aimed at improving efficacy, tolerability, and resistance profiles in oncology. Its lead candidate, ADCX-020, is progressing toward first-in-human studies, with IND and CTA filings targeted for the end of 2025. In parallel, the company is expanding a broader pipeline of differentiated ADCs that leverage its novel payload platform. Founded about 18 months ago and led by CEO and founder Jack Elands, the team draws on deep scientific and commercial expertise in the ADC field. The company positions itself as a European leader in next-generation ADC innovation, emphasizing precision targeting and payload differentiation. With the recent €105 million Series A financing, Adcytherix now has substantial resources to transition from preclinical research to clinical development. The new capital underpins both the advancement of ADCX-020 and the ongoing build-out of its proprietary ADC platform.

Participated · Series A · Mar 2025

Callio Therapeutics is focused on developing next-generation multi-payload antibody-drug conjugates that deliver combinations of payloads to tumor cells. Its lead program is a HER2-targeted dual-payload ADC, and the company also plans a second undisclosed ADC program. The company was created by Frazier Life Sciences and is headquartered in Seattle and Singapore. Callio in-licensed multi-payload ADC technology and associated IP from Hummingbird Bioscience under an exclusive worldwide agreement that includes equity, potential milestone payments and royalties. Management includes executives with backgrounds at ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, Hummingbird Bioscience and Genentech. The company intends to use proceeds from its recent financing to achieve clinical proof-of-concept for its pipeline.

Led · Series A · Jan 2025

AnaCardio is a privately held Swedish clinical-stage biopharmaceutical company founded in 2017 and based on research from Karolinska Institutet. Its lead candidate, AC01, is a first-in-class oral ghrelin receptor agonist designed to enhance cardiac contractility without the adverse effects typical of conventional inotropes. The company reported positive results from an initial study showing safety, target engagement, and improved contractility. Funds from the recent financing will support completion of the phase 1b/2a GOAL-HF1 study, including a 28-day cohort expansion planned for early 2025. Management positions the data and funding as enabling advancement to proof-of-concept and progression toward late-stage clinical development. AnaCardio AB is a Swedish clinical-stage biopharmaceutical company focused on developing novel therapies for heart failure. Its lead asset, AC01, is being developed for patients with heart failure and reduced ejection fraction (HFrEF). The company plans a clinical phase 1b/2a study of AC01 in HFrEF patients, expected to begin at selected centers in several European countries in fall/winter 2022. Proceeds from the recent financing will fund that planned study. AnaCardio was founded on research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The company frames heart failure as a potentially fatal disease and the most common cause of hospitalization. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure based on research from Karolinska Institutet. Its lead asset, AC01, targets improved contractility of the heart muscle through a unique and differentiated mechanism. The company completed a fundraising to progress clinical development and is preparing to start a phase 1b/2a study with AC01 in 2022. The new capital enables AnaCardio to complete those preparations and advance its clinical plans. Karolinska Development is a strategic investor and has direct ownership interest amounting to 21 percent. The financing structure and participation signal continued backing from the Nordic life-sciences ecosystem.

Participated · Series B · Dec 2024

Citryll, based in Oss, The Netherlands, is advancing a novel approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs). Its lead asset, CIT-013, is a first-in-class monoclonal antibody with a dual mechanism of action that enhances clearance of existing NETs and inhibits formation of new NETs. The company says this approach could create a new class of therapeutics with broad applications across conditions such as rheumatoid arthritis and hidradenitis suppurativa. Citryll is led by CEO Eduardo Bravo. The company intends to use the funds from its Series B to enable next steps in the clinical development of CIT-013. The technology aims to address a fundamental component of the inflammatory process that has not yet been therapeutically targeted. Citryll develops CIT-013, a therapeutic antibody designed to inhibit formation of neutrophil extracellular traps (NETs) and NETosis. The company intends to use CIT-013 to treat autoimmune and NET-driven conditions, including lupus, organ damage from sepsis, asthma and NET-induced thrombosis. Citryll says CIT-013 does not broadly target inflammation or acquired immunity but instead extinguishes NET-derived autoantigens and toxic, prothrombotic and proinflammatory components. Proceeds from the fundraise will advance the preclinical and clinical development and manufacturing of CIT-013. The programme’s preclinical development and manufacturing were accelerated in 2019 via a first closing with existing investors, and the program was on track to reach the clinic in 2021. Citryll describes its team as world leaders and pioneers in the NETosis space. The company is based in Oss, the Netherlands, and was founded by ModiQuest B.V. together with CEO Helmuth van Es and CSO Renato Chirivi. Citryll develops tACPA, a class of antibodies that inhibit NETosis by binding N‑terminal citrullinated histone epitopes essential for NET formation, acting downstream of the PAD‑dependent citrullination pathway. The company’s approach aims to extinguish sources of autoantigens and NET‑derived toxic molecules without broadly suppressing inflammation or acquired immunity. Citryll targets autoimmune and other diseases driven by NETs, including lupus, vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis. Proceeds from its recent financing will be used to advance pre‑clinical and clinical development of the tACPA therapeutic. Citryll was founded by ModiQuest B.V., CEO Helmuth van Es, and CSO Renato Chirivi, and is based in Oss, the Netherlands. The company positions tACPA as a first‑in‑class therapeutic innovation addressing significant medical needs where NET formation plays a crucial pathogenic role.